Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors

Carcinogenesis

Volumn 33, Issue 9, 2012, Pages 1674-1683

  Dumont, Amaury G ^a,c   Yang, Yanwen ^a   Reynoso, David ^a   Katz, Daniela ^a,b   Trent, Jonathan C ^a,c   Hughes, Dennis P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HEBREW UNIVERSITY   (Israel)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE; IMATINIB; MESSENGER RNA; NOTCH1 RECEPTOR; RETROVIRUS VECTOR; STEM CELL FACTOR; VORINOSTAT;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE SILENCING; HES1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OVERALL SURVIVAL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HOMEODOMAIN PROTEINS; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, NOTCH; REPRESSOR PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84865531135     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs221     Document Type: Article

References (48)

1. Kindblom, L.G. et al. (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am. J. Pathol., 152, 1259-1269.
2. Hirota, S. et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279, 577-580.
3. Sommer, G. et al. (2003) Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc. Natl. Acad. Sci. U.S.A., 100, 6706-6711.
4. Heinrich, M.C. et al. (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 299, 708-710.
5. Agaram, N.P. et al. (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes. Chromosomes Cancer, 47, 853-859.
6. Janeway, K.A. et al. (2011) Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc. Natl. Acad. Sci. U.S.A., 108, 314-318.
7. Dematteo, R.P. et al. (2002) Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum. Pathol., 33, 466-477.
8. Demetri, G.D. et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 347, 472-480.
9. Heinrich, M.C. et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol., 21, 4342-4349.
10. Verweij, J. et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet, 364, 1127-1134.
11. Blanke, C.D. et al. (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol., 26, 620-625.
12. Miele, L. et al. (2006) Notch signaling in cancer. Curr. Mol. Med., 6, 905-918.
13. Miele, L. et al. (2006) NOTCH signaling as a novel cancer therapeutic target. Curr. Cancer Drug Targets, 6, 313-323.
14. Ranganathan, P. et al. (2011) Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer, 11, 338-351.
15. Mizutani, T. et al. (2001) Conservation of the biochemical mechanisms of signal transduction among mammalian Notch family members. Proc. Natl. Acad. Sci. U.S.A., 98, 9026-9031.
16. Kunnimalaiyaan, M. et al. (2007) Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist, 12, 535-542.
17. Zweidler-McKay, P.A. et al. (2005) Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood, 106, 3898-3906.
18. Dotto, G.P. (2008) Notch tumor suppressor function. Oncogene, 27, 5115-5123.
19. Klinakis, A. et al. (2011) A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature, 473, 230-233.
20. Agrawal, N. et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science, 333, 1154-1157.
21. Stransky, N. et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science, 333, 1157-1160.
22. Radtke, F. et al. (2003) The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat. Rev. Cancer, 3, 756-767.
23. Artavanis-Tsakonas, S. et al. (1999) Notch signaling: cell fate control and signal integration in development. Science, 284, 770-776.
24. Nickoloff, B.J. et al. (2003) Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene, 22, 6598-6608.
25. Borggrefe, T. et al. (2009) The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell. Mol. Life Sci., 66, 1631-1646.
26. Iso, T. et al. (2003) HES and HERP families: multiple effectors of the Notch signaling pathway. J. Cell. Physiol., 194, 237-255.
27. Bümming, P. et al. (2007) Gastrointestinal stromal tumors regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype. Endocr. Relat. Cancer, 14, 853-863.
28. Modlin, I.M. et al. (2006) Evolution of the diffuse neuroendocrine system- clear cells and cloudy origins. Neuroendocrinology, 84, 69-82.
29. Greenblatt, D.Y. et al. (2008) Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann. Surg., 247, 1036-1040.
30. Greenblatt, D.Y. et al. (2007) Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist, 12, 942-951.
31. Greenblatt, D.Y. et al. (2007) Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. J. Gastrointest. Surg., 11, 1515-1520; discussion 1520.
32. Adler, J.T. et al. (2008) Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery, 144, 956-961; discussion 961.
33. Mühlenberg, T. et al. (2009) Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res., 69, 6941-6950.
34. Taguchi, T. et al. (2002) Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab. Invest., 82, 663-665.
35. Tuveson, D.A. et al. (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 20, 5054-5058.
36. Rossi, S. et al. (2006) Gastrointestinal stromal tumours overexpress fatty acid synthase. J. Pathol., 209, 369-375.
37. Reynoso, D. et al. (2011) Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol. Oncol., 5, 93-104.
38. Livak, K.J. et al. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
39. Pear, W.S. et al. (1998) Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/ abl-transduced bone marrow. Blood, 92, 3780-3792.
40. Zhang, P. et al. (2010) Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. Oncogene, 29, 2916-2926.
41. Geryk-Hall, M. et al. (2010) Driven to death: inhibition of farnesylation increases Ras activity in osteosarcoma and promotes growth arrest and cell death. Mol. Cancer Ther., 9, 1111-1119.
42. Zhang, P. et al. (2008) Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin. Cancer Res., 14, 2962-2969.
43. McAuliffe, J.C. et al. (2009) A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann. Surg. Oncol., 16, 910-919.
44. Okamura, Y. et al. (2008) Notch signaling is required for the maintenance of enteric neural crest progenitors. Development, 135, 3555-3565.
45. Gunawan, B. et al. (2007) An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications. J. Pathol., 211, 463-470.
46. Ylipää, A. et al. (2011) Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer, 117, 380-389.
47. Wozniak, A. et al. (2007) Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes. Chromosomes Cancer, 46, 261-276.
48. Meza-Zepeda, L.A. et al. (2006) Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas. Cancer Res., 66, 8984-8993.